Search

everythinglearnresearchcommunity

for

Search:↓

A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.

Upadacitinib may effectively treat resistant lichen planopilaris.

LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

PEA-ENL improves skin delivery and reduces inflammation without side effects.

Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.

Liposomes can improve the effectiveness of skin treatments.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Scientists found new, better-working inhibitors for a hormone-related enzyme.

Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.

Drugs targeting EMT molecules show promise for treating lichen planopilaris.

Diphenyl ethers can potentially reduce excess oil production when applied on the skin, helping treat conditions like acne.

Enhanced stem cells from the placenta can reduce fat cell formation in eye disease.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.

New compounds show promise for treating benign prostate hyperplasia with fewer side effects.

Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.

GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.

The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.

Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.

GLP-1 receptor analogs may help improve metabolism and reproductive health in people with PCOS and obesity.

Elagolix did not effectively treat polycystic ovary syndrome.

A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.

Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.

PPARα agonists may help treat alopecia areata by reducing inflammation.

Cadd4 effectively reduces cholesterol levels without side effects.

Mycophenolate mofetil may improve symptoms and stop hair loss in Lichen planopilaris, but more research is needed.

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.